This implies that passive immunization with tau antibodies is a practical therapeutic target and that the CSF level of p-tau262/356 or in the microtubule binding domain (MTBD) can serve as a beneficial biomarker of tau pathology to observe tau therapeutics in medical trials.To Jubao Duan of your College of Chicago, the authors deliver powerful proo